Bronchial Artery Embolization with Large Sized (700–900 µm) Tris-acryl Microspheres (Embosphere) for Massive Hemoptysis: Long-Term Results (Clinical Research)

Kucukay, F. | Topcuoglu, O.M. | Alpar, A. | Altay, Ç.M. | Kucukay, M.B. | Ozbulbul, N.I.

Article | 2018 | CardioVascular and Interventional Radiology41 ( 2 ) , pp.225 - 230

Purpose: To investigate the safety, efficacy and long-term results of bronchial artery embolization with microsphere particles (Embosphere® Microspheres, BioSphere Medical, Rockland, MA) 700–900 µm in size for massive hemoptysis. Methods: One hundred and seventy-four patients (94 female, 80 male; mean age 39.4 ± 5.7) who had bronchial artery embolization for massive hemoptysis between January 2010 and October 2015 were incorporated in the study. Patients had hemoptysis with a mean volume of 525 ± 150 mL (median 500 mL, range 300–1200 mL) over a 24-h period. Underlying pathologies included bronchial artery hypertrophy due to bronchie . . .ctasis (56.3% [98/174]), lung cancer (29.9% [52/174]), tuberculosis (10.3% [18/174]) and the rest remained idiopathic (3.4% [6/174]). Mean bronchial artery diameter before the intervention was 3.8 ± 1.5 mm (median 4 mm, range 3.1–7.5 mm). Median follow-up period was 56 months (range 10–82 months). Primary objectives were the technical and clinical success. Results: Technical success was 100%. Clinical success for preventing massive hemoptysis was 91.9% (160/174). There was no procedure-related mortality or morbidities. Minor complications such as chest pain were observed in nine patients (5.0%). Recurrent hemoptysis (8.1%) was observed within 6 months in 14 patients, ten of whom were treated with a second embolization session and the remaining four with a total of three embolization sessions. Conclusion: Bronchial artery embolization for massive hemoptysis with Embosphere particles 700–900 µm in size is a safe and effective method with high technical and clinical success rates. Long-term results are excellent. © 2017, Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Daha fazlası Daha az

Intra-arterial Ultra-low-Dose CT Angiography of Lower Extremity in Diabetic Patients

Özgen, A. | Sanioğlu, S. | Bingöl, U.A.

Article | 2016 | CardioVascular and Interventional Radiology39 ( 8 ) , pp.1165 - 1169

Purpose: To image lower extremity arteries by CT angiography using a very low-dose intra-arterial contrast medium in patients with high risk of developing contrast-induced nephropathy (CIN). Materials and Methods: Three cases with long-standing diabetes mellitus and signs of lower extremity atherosclerotic disease were evaluated by CT angiography using 0.1 ml/kg of the body weight of contrast medium given via 10-cm-long 4F introducer by puncturing the CFA. Images were evaluated by an interventional radiologist and a cardiovascular surgeon. Density values of the lower extremity arteries were also calculated. Findings in two cases wer . . .e compared with digital subtraction angiography images performed for percutaneous revascularization. Blood creatinine levels were followed for possible CIN. Results: Intra-arterial CT angiography images were considered diagnostic in all patients and optimal in one patient. No patient developed CIN after intra-arterial CT angiography, while one patient developed CIN after percutaneous intervention. Conclusion: Intra-arterial CT angiography of lower extremity might be performed in selected patients with high risk of developing CIN. Our limited experience suggests that as low as of 0.1 ml/kg of the body weight of contrast medium may result in adequate diagnostic imaging. © 2016, Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.